Commenting on the trial update, Tim McCarthy, Chairman of ImmuPharma LON:IMM said: “We are pleased to give DireectorsTalk a further update of our pivotal Phase III study of Lupuzor(TM) in Lupus showing that approximately a quarter of the patients have now completed the full 12 months of the trial and almost all the patients have completed six months. As the trial continues to progress, we are delighted to observe the continuation of our robust safety record, as Lupuzor(TM) is being administered to greater numbers of patients over a longer period of time.
With the study on track to report top line results in Q1 2018, we look forward to providing shareholders with further updates on this pivotal Phase III study as it progresses through the second half of 2017.
We are also delighted that following our AGM being held later today, we will be hosting an Investor Presentation which will provide the Board with an opportunity of talking through the Lupuzor(TM) trial as well providing further details on the other clinical development products in our pipeline.”
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, has given DirectorsTalk an update of its pivotal 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor(TM), its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease. This is in advance to the Company’s Annual General Meeting (AGM) which will be held later today at 10:30am at Sky Light City Tower, 50 Basinghall Street, EC2V 5DE.
ImmuPharma will also be hosting an Investor Presentation and luncheon immediately following the AGM at 11.30am. Vadim Alexandre, Northland Capital Partners’ Healthcare Analyst will also give a short presentation. A video of the presentation will be available to view on the Company’s website from Monday 3 July 2017 on: http://www.immupharma.org/events/2017. Please contact Lisa Baderoon at lisa.baderoon@immupharma.com if you would like to attend this event.
-- Study summary as at end-June 2017 -- 200 patients successfully recruited and randomised (dosed)
o all 200 patients have passed the 3 months stage
o over 90% of patients (184) have passed 6 months
o 81 patients (40%) have passed the 9 months stage
o 46 patients (23%) have passed the full 12 months of the study
— Continued robust safety record which remains consistent with Lupuzor(TM)’s product profile as shown in its previous Phase IIb study
-- Top line results remain on track to be reported in Q1 2018
